Cryoport is expanding its impact on regenerative medicine development and distribution via a new partnership with Lonza.
Lonza is one of the world’s most-trusted integrated solutions providers to the pharmaceutical, biotech and consumer health markets. Over 15,000 full-time Lonza employees work at 100 Lonza sites and offices worldwide.
Lonza designated Cryoport its “preferred partner” to deliver critical cell and gene therapies to both commercial and clinical customers across the US, Asia, and Europe.
“There is no doubt this partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services,” said Alberto Santagostino, SVP and Head of Cell & Gene Technologies for Lonza Pharma & Biotech.